MoonLake Immunotherapeutics MLTX Return on assets
Return on assets at other companies
Other financials
Where this comes from
Calculated from MoonLake Immunotherapeutics’s reported figures.
Based on trailing twelve months.
The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about MoonLake Immunotherapeutics's return on assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is MoonLake Immunotherapeutics's return on assets?
- MoonLake Immunotherapeutics (MLTX) reported return on assets of -56.4% in Q1 2026.
- How has MoonLake Immunotherapeutics's return on assets changed year-over-year?
- MoonLake Immunotherapeutics's return on assets decreased by 108.8% year-over-year, from -27% to -56.4%.
- What is the long-term trend for MoonLake Immunotherapeutics's return on assets?
- Over 4 years (2021 to 2025), MoonLake Immunotherapeutics's return on assets has grown at a -23.5% compound annual growth rate (CAGR), from -146.8% to -50.4%.
- What does return on assets mean?
- Trailing-twelve-month net income divided by average total assets. Measures how efficiently the asset base generates profit, independent of how those assets are financed. Computed as net income over average total assets — note this is OpenCapital's standard definition and may differ from data vendors that use alternative numerators.